Zyprexa, Zydis, Olanzapine News

World's oldest Christian Bible is reunited, digitized Getting waxed Movie: Legally Blonde 2: Red, White & Blonde Ellen Gray: A 'Warehouse' of secrets on Syfy Fumo, Carolyn Zinni engaged She weeps for son, and his accused killer Tips for boosting dad's profile on child matters Fathers looking to step up feel invisible READER FEEDBACK Posted on Tue, ...

Bill Wiggins believes a powerful antipsychotic medication helped save his wife, Kathye.

Medical research out of the University of British Columbia suggests the number of children taking medications known as atypical antipsychotics has increased tenfold over the past decade, CBC News has learned.

Imagine piling on a shocking 70kg in eight months and being told by your doctor you were helpless to stop it.

A new study by Rudolph M. Navari, director of the University of Notre Dame's Walther Cancer Research Center, and Marie C. Brenner, a Notre Dame graduate who is a student at Loyola University Medical School in Chicago, describes how a novel combination of two drugs continues to show great promise in treating cancer-related anorexia .

The so called "Zyprexa documents" are examples of internal pharmaceutical company documents that have been subpoenaed to court cases in the USA and other countries.

On June 11, 2009, FDA News reported that AstraZenecaa s Seroquel, Pfizera s Geodon and Eli Lillya s Zyprexa atypical antipsychotics "won an FDA advisory panela s recommendations for approval to treat schizophrenia and bipolar disorder in pediatric and adolescent patients." [ News Source ] Posted in Malpractice lawsuit

We posted a number of times about questionable practices Eli Lilly used to market its atypical anti-psychotic drug Zyprexa .

Jun 15, 2009 - Obecure Ltd., a subsidiary of Bio-Light Israeli Life Science Investments Ltd.

Pharmaceutical giant Eli Lily & Co. knew its product Zyprexa was ineffective for treating dementia when it pressured physicians to prescribe it to seniors from 1999 and 2003, according to a report citing recently unsealed company documents.

On June 11, 2009, FDA News reported that AstraZeneca's Seroquel, Pfizer's Geodon and Eli Lilly's Zyprexa atypical antipsychotics "won an FDA advisory panel's recommendations for approval to treat schizophrenia and bipolar disorder in pediatric and adolescent patients." "The FDA's expanded marketing approval process for antipsychotics, highly toxic ...

The FDA will decide today if three antipsychotic drugs that are commonly used to treat adults are also safe for use by children.

Eli Lilly & Co. urged doctors to prescribe Zyprexa for elderly patients with dementia, an unapproved use for the antipsychotic, even though the drugmaker had evidence the medicine didna t work for such patients, according to unsealed internal company documents.

Even as a US District Court prepares 6,000 Seroquel lawsuits for trial, Eli Lilly pays $1.42 billion for illegal Zyrexa marketing and 30 states sue over heisted Medicaid funds for atypical antipsychotics, an FDA advisory panel has recommended approval of Seroquel, Zyrexa and Geodon for children.

The U.S. Food and Drug Administration Psychopharmacologic Drugs Advisory Committee voted that Zyprexa , an atypical antipsychotic, is effective and acceptably safe for the acute treatment of schizophrenia or manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old.

As a new feature of CNNhealth.com, our team of expert doctors will answer readers' questions.

A U.S. Food and Drug Administration advisory panel voted overwhelmingly Wednesday that Seroquel and Zyprexa, two powerful antipsychotic drugs, be approved to treat schizophrenia and bipolar disorder in children aged 13 to 17.

Zyprexa, on an assembly line here, is one of three drugs on which the FDA advisers will vote for use by patients under 18.

A panel of medical experts for the federal Food and Drug Administration is being asked to approve three powerful and expensive antipsychotic drugs for use in children.

Three antipsychotic drugs appear to work in children and teens but their risks must be weighed as the makers aim to promote the medicines for youth, U.S. drug reviewers said in documents released on Friday.